UC Davis Comprehensive Cancer Center

Cancer parametric PET imaging with radioactive tracers is reduced from an hour to 20 minutes

Clinical trial tests new treatment approach, offers hope for personalized therapies.

Findings point to a biomarker that may give a “head start” to triple-negative breast cancer in Black women.

New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.

April is Head and Neck Cancer Awareness Month, and a promising new research initiative at UC Davis Comprehensive Cancer Center could lead to a new and far more effective standard of care for this group of cancers.

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.